Expertise in
7
conditions

Maria C. Finazzi

Bergamo, IT 
Expertise in
7
conditions
Bergamo, IT 

Overview

Maria Finazzi practices practicing medicine in Bergamo, Italy.

Ms. Finazzi is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Bone Marrow Transplant, and Splenectomy.

She is actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Bergamo, Italy
Other Locations
Milan, Italy
20133, Italy
Monza, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (allo-SCT)
Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (allo-SCT)
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Combination product
Study Phase: Phase 2
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
View 1 Less Clinical Trial

57 Total Publications

Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.
Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.
Journal: Transplantation and cellular therapy
Published: April 14, 2026

Frequently Asked Questions about Maria C. Finazzi

Is Maria C. Finazzi a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Maria C. Finazzi is classified as an Distinguished expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Maria C. Finazzi participate in research or clinical trials?

Yes. Maria C. Finazzi has published 57 articles and abstracts on conditions like Myelofibrosis. You can view a list of Maria C. Finazzi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Finazzi's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile